Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL4370506 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL1617251 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL6046437 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL6046435 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL1617625 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL1936216 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL6046494 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL1247518 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL3283790 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E | |
| Ethylene Glycol SCHEMBL19210022 | 1.00 | GAA (0.52) | GAAALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120020119-A | Process for preparing N- (2-substituted ethyl) amides and N-vinyl amides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-117865858-A | Novel PET imaging agent targeting cannabinoid type 2 receptor, preparation method and application thereof | 浙江大学 | 2024-04-12 | — | — | CN | claimed |
| CN-114989166-B | Tumor KRAS G12C mutation targeting positron tracer agent, preparation method and application | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| CN-114989166-A | Tumor KRAS G12C mutation targeted positron tracer, preparation method and application | 中国人民解放军空军军医大学 | 2022-09-02 | — | — | CN | claimed |
| CN-108017593-B | Simple, convenient and efficient 1-oxo-4, 5-diazepane synthesis method | 东南大学 | 2021-05-11 | — | — | CN | claimed |
| CN-110734426-A | Acetylcholinesterase degradation compound and preparation method and application thereof | 浙江省医学科学院 | 2020-01-31 | — | — | CN | claimed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | claimed |
| US-6776930-B2 | POLYMER BONDED TO DYE | EASTMAN KODAK COMPANY | 2004-08-17 | — | — | US | claimed |
| US-20010023938-A1 | Polymer bonded to dye | ALLEN MAX (US) | 2001-09-27 | — | — | US | claimed |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | disclosed |
| CN-116283955-B | Compound for targeted degradation of HDAC7, and preparation method and application thereof | 浙江大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-120020119-A | Process for preparing N- (2-substituted ethyl) amides and N-vinyl amides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-115819193-B | Synthesis method of binary symmetrical hydrofluoroether | 浙江诺亚氟化工有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118065133-A | Unsaturated ion phosphonate composition and preparation method thereof | 江苏海洋大学 | 2024-05-24 | — | — | CN | disclosed |
| EP-0747448-A2 | Rigidized monomethine cyanine dyes | CARNEGIE-MELLON UNIVERSITY (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5545785-A | Process for preparing biscyclopentadienyl compounds | WITCO GMBH (DE) | 1996-08-13 | — | — | US | disclosed |
| EP-0343897-A1 | Seawater-insoluble hydrolysable polymers and marine anti-fouling paint containing them | COURTAULDS COATINGS (HOLDINGS) LIMITED (GB) | 1989-11-29 | — | — | EP | disclosed |
| US-4492788-A | Partially deacylated ultra-high molecular weight poly(N-propionylethylenimines) | ALLIED CORPORATION (US) | 1985-01-08 | — | — | US | disclosed |
| US-4137080-A | POLYFUNCTIONAL COUPLER AND DEVELOPER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1979-01-30 | — | — | US | disclosed |
| US-4064260-A | Anti-inflammatory diarylimidazothiazoles and their corresponding S-oxides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | PIK3R5, PIK3CA, PIK3R1 | GAA 1385/4885ALDH1A1 2788/4885SMN1; SMN2 4463/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | GAA 4210/4885ALDH1A1 4339/4885SMN1; SMN2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.